Company
NYSE:LLY
Eli Lilly and Co is engaged in drug manufacturing businesses. The company discovers, develops, manufactures and markets products in the human pharmaceutical products segment.
148 stories · page 2 of 2
"Lilly delivered strong results once more in the second quarter in terms of operational performance, pipeline advancements and strategic objectives," said David Ricks, the company's chairman and CEO.
The Dow Jones Industrial Average closed down around 13 points at 25,044 but today futures are up 87 points.
AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years
An FDA advisory committee does not recommend use of arthritis drug baricitinib at a higher dosage
The pharma giant will take a charge of US$0.05 a share in the second quarter as a result of the transaction
It’s the second time regulators have given the thumbs-down to Vitaros, with the FDA flagging concerns over one of the ingredients in the cream as well as with the manufacturing process
Proactive takes a look at what's moving the needle in pre-market ahead of what looks like an earnings-fuelled day
Strong demand for its recently-launched products including its new diabetes and psoriasis drugs is likely to push up sales next year
The drugmaker also told investors that it was looking at various options, including the possible sale or even an IPO for its Elanco Animal Health business
The detailed results from the 12-month, open-label Phase 3 study will be presented today
Just days after cinemas owner issued a profit warning it released its second quarter numbers, and they were not quite the horror picture the market had been expecting
Eli Lilly and Co. will apply for approval of lasmiditan in the second half of next year
The halt will remain in place until Friday 28th July 2017.
A delay for a new drug application somewhat overshadowed better than expected results.
A phase III trial is currently underway and includes six studies in 7,000 patients suffering osteoarthritis, chronic low back pain and cancer.
Some 531 patients with urothelial carcinoma were treated in the trial
US benchmarks closed higher on Tuesday as traders await more on Trump's tax plans
Abemaciclib is also being tested in trials for for lung cancer, brain metastases and pancreatic cancer.
Rheumatoid arthritis affects the joints and more than 23mln people worldwide
The fourth quarter EPS was a little shy of expectations, but the shares still rose
Growth in its portfolio of new products was behind the better than expected forecasts.
US top stocks inched their way out of intraday deficit and closed at fresh record highs on Wednesday after Federal Reserve meeting minutes were released.
US stocks snapped back from initial losses to close Wednesday higher and the Dow even managed an intraday record peak, while small-caps had one of their best days in 14 years, after Donald Trump and the Republicans’ sweep into office
Shares of Regeneron Pharmaceuticals and Teva Pharmaceuticals were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing
Archive
Pfizer bruised by a downgrade from Jefferies but Wedbush assume coverage of eCommerce names eBay and Etsy
BACE inhibitors are the latest glimmer of hope for the treatment of Alzheimer’s disease.
Regen will receive compounds from Lilly for drug discovery purposes
Lilly has made what’s known as a milestone payment following progress in developing a treatment called AZD3293 for early stage Alzheimer's disease.
Archive
Broker Jefferies has cut its rating on drugs giant AstraZeneca PLC to 'hold' from 'buy' saying there's a lack of catalysts in 2016 to re-rate shares.
US shares were stabilising but still mixed heading into Tuesday's close.
Heavy losses were pared late in the day and in fact the Dow and the S&P moved into positive territory
Shares in US drugs giant Eli Lilly & Co fell over 2% in pre-market deals as it cuts its earnings guidance for the 2015 year.
Investments and investor services
Eli Lilly led blue-chips lower after scrapping work on its lead heart drug but news of Ferrari's flotation set petrolheads' pulses racing.
Two-and-a-half days of losses have taken the benchmark index below the level at which it started the year.
Pundits are no wiser after yesterday's policy statement from the Federal Open Market Committee as to the timing of the long-expected interest rate hike.
Shares in Eli Lilly were among the few blue-chips making headway on Thursday after a positive result in a diabetes study.
Investments and investor services
Pundits are no wiser after yesterday's policy statement from the FOMC as to the timing of the long-expected interest rate hike.
Pundits are no wiser after yesterday's policy statement as to the timing of the long-expected interest rate hike.
Wall Street retreated for the third straight session today following disappointing results and forecasts from companies including 3M and Caterpillar, adding to U.S. profit concerns. The S&P 500 (INDEXSP:.INX) skidded 0.6 percent to 2,10
U.S. index-futures pointed higher ahead of another earnings-heavy trading session and data showed weekly jobless claims plunged to the lowest level since 1973. Futures for the Nasdaq 100 index rose 0.2 percent to 4,626, indicating the index
U.S. stocks headed sharply lower in late trading today as losses among industrials, energy and financials weighed on broader indexes, while investors watched for a breakthrough in Greek debt talks. The S&P 500 (INDEXSP:.INX) fell 0.2 pe
U.S. stock-index futures were trading higher today, with updates about the labor market and consumer spending on tap, while investors eye speeches by Federal Reserve officials as interest-rate hikes loom. Futures for the Dow Jones Industria
